Urolithin A and the Immune System: The 2025 MitoImmune Trial Results

Key Takeaways

• The 2025 MitoImmune trial (Nature Aging) demonstrated that 4 weeks of Urolithin A supplementation improved immune cell function and reduced inflammatory markers in 50 middle-aged adults.
• This is the first clinical evidence that mitochondrial enhancement directly rejuvenates aspects of the aging immune system.
• The mechanism: improved mitochondrial quality in T cells and NK cells supports proper immune surveillance and function.
• Combined with the original 2019 Nature Metabolism mitophagy trial, Urolithin A now has the strongest human RCT evidence of any mitophagy-targeting supplement.
• Practical implications extend beyond immune function: improved immune surveillance is mechanistically linked to senescent cell clearance and cancer prevention.

The Mitochondrial-Immune Connection

Immune cells are extraordinarily energy-demanding. T cell activation, antibody production, and pathogen response all require massive ATP output. When mitochondria function poorly, immune cells function poorly — producing a key feature of aging called immunosenescence.

Age-related immune decline involves:

• Reduced naive T cell production (thymic involution)
• Increased "exhausted" T cells with dysfunctional mitochondria
• Reduced cytotoxic capacity of NK cells
• Increased chronic low-grade inflammation (inflammaging)
• Reduced response to vaccines
• Increased susceptibility to infections
• Reduced clearance of senescent cells and emerging cancer cells

Targeting mitochondrial function in immune cells has been a longstanding theoretical interest in longevity medicine — but lacked clinical validation until 2025.

Urolithin A

The 2025 MitoImmune Trial

Published in Nature Aging (Liu et al., 2025), the MitoImmune trial provided the first clinical demonstration that a supplement can improve aging-related immune dysfunction:

Design:

• 50 middle-aged adults (ages 50-65) with elevated inflammatory markers
• Randomised to Mitopure (Urolithin A 500mg/day) or placebo
• 4-week supplementation duration
• Detailed immune phenotyping pre/post

Primary findings:

• Significantly improved immune cell function across multiple metrics
• Reduced inflammatory markers including CRP and IL-6
• Enhanced mitochondrial function in immune cells
• Improved composition of T cell and NK cell subsets

The 4-week timeline is notable — meaningful immune improvements emerged within a month, suggesting Urolithin A acts on mechanisms that don't require long-term remodelling.

The Mechanism: Mitophagy in Immune Cells

Urolithin A's primary mechanism is mitophagy — the autophagic clearance of damaged mitochondria. The 2019 Nature Metabolism trial (Andreux et al.) demonstrated this in skeletal muscle. The MitoImmune findings extend this to immune cells:

The cascade:

1. Aging immune cells accumulate damaged mitochondria
2. Damaged mitochondria produce excessive ROS, leak DAMPs, and reduce ATP output
3. Immune cell function (cytotoxicity, signalling, motility) is impaired
4. Urolithin A activates PINK1/Parkin pathway, clearing damaged mitochondria
5. New, functional mitochondria replace them through biogenesis
6. Immune cell function is restored

This mechanism is fundamentally different from immunostimulants — Urolithin A doesn't push the immune system harder; it removes the cellular obstacles to proper function.

The Inflammation Reduction

The reduction in CRP and IL-6 is particularly significant. Inflammaging — chronic low-grade inflammation in aging — is mechanistically linked to:

• Cardiovascular disease
• Type 2 diabetes
• Alzheimer's disease
• Cancer
• Sarcopenia
• Frailty

Most anti-inflammatory interventions work either by suppressing inflammation broadly (with infection risk) or by addressing specific pathways. Urolithin A's mechanism — restoring mitochondrial function in immune cells — represents a fundamentally different approach: enabling proper immune function rather than suppressing inflammation.

The MitoImmune trial demonstrated that this approach produces measurable reductions in inflammation markers without immunosuppression.

Senolytic Implications

A separate mechanism with major implications: improved immune surveillance enables better senescent cell clearance.

Senescent cells are normally cleared by the immune system — particularly by NK cells and cytotoxic T cells. Age-related immune decline impairs this clearance, allowing senescent cells to accumulate. The accumulated senescent cells drive inflammaging through SASP secretion, creating a vicious cycle.

Urolithin A's restoration of immune cell function:

• Increases NK cell cytotoxic capacity
• Enhances T cell function (including granzyme B production)
• Improves immune surveillance of damaged cells
• Indirectly reduces senescent cell burden through improved clearance

This connects Urolithin A mechanistically to the senolytic field — though through immune restoration rather than direct senescent cell killing.

The Combined Evidence Base

Urolithin A now has the strongest human RCT evidence of any mitophagy-targeting supplement:

2019 Nature Metabolism (Andreux et al.):

• First proof of concept in humans
• 250-1000mg doses produced measurable mitophagy gene expression changes
• Improved muscle mitochondrial function

2022 JAMA Network Open (Singh et al.):

• 4-month trial, 66 older adults
• Improved muscle endurance and strength
• Reduced plasma C-reactive protein

2025 Nature Aging (Liu et al.):

• MitoImmune trial
• Improved immune cell function
• Reduced inflammatory markers

Multiple ongoing trials:

• Cardiovascular outcomes (mechanistic studies)
• Neurological applications (Parkinson's, mild cognitive impairment)
• Sports nutrition applications
• Bone density

The pattern is consistent: Urolithin A produces measurable improvements in multiple aging-related mechanisms with an excellent safety profile.

The Bioavailability Issue

Urolithin A is the metabolite produced when gut bacteria process ellagitannins (found in pomegranates, walnuts, and certain berries). The problem: only 30-40% of adults produce significant amounts of Urolithin A from dietary ellagitannins — the rest lack the necessary gut bacteria.

This is why direct Urolithin A supplementation (Mitopure) is so important:

• Bypasses the microbiome conversion requirement
• Ensures consistent dose
• The form used in all positive clinical trials

Eating pomegranates and walnuts is healthy but unreliable as a Urolithin A source for the majority of people.

Dosing and Forms

Mitopure (Amazentis/Timeline) is the patented Urolithin A formulation used in all published clinical trials. Standard dosing:

• 500mg/day for general use (MitoImmune trial dose)
• 1000mg/day for muscle and metabolic applications
• 250mg/day as minimum effective dose for some applications

Other Urolithin A supplements have entered the market. Quality varies; the patented Mitopure form has the clinical trial evidence behind it.

Timing: With or without food. Half-life supports once-daily dosing.

Duration to effect:

• 4 weeks for immune markers (MitoImmune)
• 4 months for muscle function (2022 trial)
• 8-12 weeks for most subjective effects
• Continuous use likely required to maintain benefits

Stacking Considerations

Urolithin A combines well with:

• Astaxanthin — different mitochondrial mechanism, complementary
• CoQ10/Ubiquinol — electron transport support + mitophagy = broad mitochondrial care
• NMN/NR — NAD+ supports mitochondrial energy + Urolithin A clears damaged mitochondria
• Omega-3 — anti-inflammatory synergy
• Quercetin/Fisetin — direct senolytic + immune-mediated senolytic via improved immune function

The combination of Urolithin A + Quercetin + SGLT2 inhibitor would target senescent cells through three complementary mechanisms — direct senolysis (Quercetin), immune-mediated clearance via PD-L1 (SGLT2), and immune surveillance restoration (Urolithin A).

Who Should Consider Urolithin A?

Strong candidates:

• Adults 40+ with elevated inflammatory markers (CRP, IL-6)
• Those concerned about immune aging
• Sarcopenia or muscle weakness concerns
• Cardiovascular disease or risk factors
• General longevity supplementation foundation

Reasonable candidates:

• Athletes seeking recovery support
• Individuals with chronic fatigue
• Those on mitochondrial longevity stacks

Less compelling:

• Young, healthy adults under 35
• Those with severe immunocompromise (theoretical considerations)
• Cost-sensitive individuals (Mitopure is premium-priced)

The Cost Consideration

Urolithin A is expensive. Mitopure typically costs:

• $60-90/month for 500mg daily dosing
• $120-180/month for 1000mg daily dosing

Generic Urolithin A supplements cost less but lack the clinical trial validation. The premium for Mitopure reflects both the patented production technology and the clinical evidence base.

For comparison:

• Annual Mitopure cost (500mg/day): ~$900
• Annual Mitopure cost (1000mg/day): ~$1,800

This positions Urolithin A as a premium longevity intervention rather than a foundational supplement. Cost-benefit analysis depends on individual priorities and budget.

What's Next for Urolithin A Research

Active research directions:

• Cognitive applications — mitochondrial mechanisms relevant to neurodegeneration
• Cardiovascular outcomes — building on immune findings
• Combination protocols — with NMN, CoQ10, senolytics
• Optimal dosing — refinement of dose-response curves
• Longer-term effects — extending beyond 4-month trial durations

The MitoImmune trial represents one step in an expanding evidence base — likely to be followed by additional findings as research continues.

Practical Recommendations

For adults 40+ considering Urolithin A supplementation:

1. Start with 500mg/day (Mitopure or equivalent quality)
2. Continue minimum 12 weeks before evaluating effects
3. Track relevant markers: hs-CRP at baseline and 12 weeks; subjective energy/recovery
4. Combine with foundational longevity supplementation rather than as standalone intervention
5. Re-evaluate at 6 months — continue if measurable benefits; reduce/discontinue if not

The MitoImmune trial provides solid validation that Urolithin A delivers measurable benefits in middle-aged adults with elevated inflammation. Whether those benefits translate to clinically meaningful longevity outcomes will require longer-term studies — but the mechanism and short-term evidence are increasingly compelling.

Frequently Asked Questions

Does Urolithin A actually improve immune function in humans?

Yes. The 2025 MitoImmune trial (Nature Aging) demonstrated that 500mg/day of Urolithin A for 4 weeks significantly improved immune cell function and reduced inflammatory markers (CRP, IL-6) in 50 middle-aged adults aged 50-65. This is the first RCT evidence of immune rejuvenation from a mitophagy-targeting supplement.

Can you get enough Urolithin A from pomegranate juice?

For most people, no. Only 30-40% of adults have the gut bacteria required to convert dietary ellagitannins (from pomegranates, walnuts, berries) into Urolithin A. Direct supplementation with Mitopure bypasses this microbiome dependency and provides the consistent dosing used in all positive clinical trials.

How long does Urolithin A take to work?

Immune marker improvements were measurable at 4 weeks in the MitoImmune trial. Muscle function improvements took 4 months in the 2022 JAMA Network Open trial. Most people notice subjective effects (energy, recovery) at 8-12 weeks. Continuous use is likely needed to maintain benefits.

Is Urolithin A the same as a senolytic like quercetin or fisetin?

Not exactly. Quercetin and fisetin directly kill senescent cells by inhibiting their survival pathways. Urolithin A works indirectly — by restoring immune cell function through mitophagy, it enhances the immune system's natural ability to clear senescent cells. The two approaches are complementary and can be combined.

What is the best dose of Urolithin A for longevity?

The MitoImmune trial used 500mg/day, which produced significant immune and inflammation improvements. The 2022 muscle trial used 1000mg/day. For general longevity supplementation, 500mg/day is the well-supported starting dose. The minimum effective dose appears to be 250mg/day for some applications, though most evidence supports 500-1000mg/day.

Related Research

• SGLT2 Inhibitors: The First Drugs That Reverse Telomere Aging in Humans
• The Senolytic Stack 2026: Quercetin + Fisetin + SGLT2 Combined Protocol
• Berberine vs Metformin: The 2026 Update on Metabolic Longevity

Scientific References

1. Liu S, et al. A natural compound revitalizes the aging human immune system (MitoImmune trial). Nature Aging (2025).

2. Andreux PA, et al. The mitophagy activator urolithin A is safe and induces a molecular signature of improved mitochondrial and cellular health in humans. Nature Metabolism (2019). PMID 32694802

3. Singh A, et al. Urolithin A improves muscle strength, exercise performance, and biomarkers of mitochondrial health in a randomized trial. JAMA Network Open (2022). PMID 35587349

4. D'Amico D, et al. Impact of the natural compound urolithin A on health, disease, and aging. Trends in Molecular Medicine (2021). PMID 33518467

5. Mallet D, et al. Urolithin A abolishes high anxiety and rescues the associated mitochondria-related transcriptomic signatures and synaptic function. Molecular Psychiatry (2025).